Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib in Lupus Nephritis
NCT02176486Phase 1Terminated
- Sponsor
- Takeda
- Start
- Jun 2014
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, randomised, double-blind trial of ixazomib in lupus nephritis (LN) (5 arms), sponsored by Takeda. Primary endpoints: Percentage of Participants Who Experienced at Least One Grade Greater Than or Equal to (>=) 2 Treatment Emergent Adverse Event (TEAE) at Day 101, Percentage of Participants Who Experienced at Least One Treatment Emergent Serious Adverse Event (SAE) at Day 101 and 2 more. Started Jun 2014; status: terminated.
02
Drugs
ixazomib
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT02176486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02176486.